- Nachrichtendetail
-
20.06.2024 14:55:03 - dpa-AFX: *GILEAD'S LENACAPAVIR SHOWS 100% EFFICACY IN HIV PREVENTION FOR CISGENDER WOMEN IN PHASE 3 TRIAL
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
GILEAD SCIENCES DL-,001 | 885823 | Frankfurt | 63,800 | 08.07.24 08:44:17 | +2,410 | +3,93% | 63,620 | 63,800 | 63,470 | 61,390 |
